10 Most Promising Cancer Stocks According to Wall Street Analysts

7. Tyra Biosciences, Inc. (NASDAQ:TYRA)

Price Target Upside: 71.30%

Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list.

TheFly reported on June 17 that Oppenheimer initiated coverage of TYRA with an Outperform rating and a $50 price target. The firm highlighted TYRA’s upcoming clinical milestones, particularly the expected three-month complete response data from the SURF302 study in induction-refractory non-muscle invasive bladder cancer, anticipated in August 2026. Following discussions with company management, Oppenheimer expressed increased confidence in TYRA’s outlook. The firm also noted the company’s strong cash position of $383.5 million, expected to support operations into the second half of 2028, while viewing its oral treatment approach as a potential advantage in a disease area marked by repeated procedures and recurrence challenges.

Earlier on May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) released its first quarter 2026 financial results, reporting increased investment in clinical development programs. Research and development expenses reached $33.5 million for the quarter ended March 31, 2026, compared with $25.0 million in the prior-year period, mainly due to ongoing dabogratinib activities, including the BEACH301 and SURF302 trials and preparations for SURF303. General and administrative expenses rose to $8.5 million from $6.9 million, driven by higher personnel-related costs. The company reported a first-quarter net loss of $39.3 million, compared with a net loss of $28.1 million during the same period in 2025.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a clinical-stage biotechnology company developing precision medicines targeting FGFR biology to treat cancer and genetically defined diseases.